USP 797 Category 1, 2 and 3 CSPs Explained

Under USP 797/800, every compounded sterile preparation, or CSP, gets sorted into Category 1, Category 2 or Category 3 by the compounding environment, the starting components and the testing the preparation received, not by the pharmacist's preference. An inspector who finds a beyond-use date the facility was not equipped to support treats the mismatch as a sterility-assurance failure, not a clerical one.

How USP 797 Sorts a CSP Into a Category

USP 797 bases the category on the compounding environment, the probability of microbial growth during storage, and how long the preparation will be used before administration. Category 1 preparations are compounded in an ISO Class 5 primary engineering control that may sit inside an unclassified segregated compounding area. Category 2 preparations are compounded inside a classified cleanroom suite, an ISO Class 7 buffer room served by an ISO Class 8 anteroom, each with its own primary engineering control. Category 3 adds requirements on top of Category 2 that the facility has to meet continuously, not only on the days it assigns a Category 3 beyond-use date.

What Each Category Requires

Personnel who compound Category 1 or Category 2 CSPs repeat garbing and aseptic-manipulation competency evaluations every six months. Category 3 compounders work to a tighter clock, repeating the same evaluations every three months. Environmental monitoring follows a similar split: viable air sampling runs at least every six months for Category 1 and Category 2 and at least monthly for Category 3, and surface sampling runs at least monthly for Category 1 and Category 2 and at least weekly for Category 3. Sterility testing is required for every Category 3 preparation, and for a Category 2 preparation only when the facility is assigning it a beyond-use date that depends on a passed sterility test.

How the Category Sets the Beyond-Use Date

The category sets the ceiling on the beyond-use date, the BUD, though the facility still has to earn the specific number within that cap. A Category 1 preparation tops out at 12 hours at room temperature or 24 hours refrigerated, a ceiling that applies regardless of whether the starting components were sterile or nonsterile. A Category 2 preparation can run from one day, for a nonsterile-component preparation with no sterility testing, up to 90 days for a terminally sterilized, sterility-tested preparation stored frozen. Category 3 is the only category that can exceed those Category 2 limits, and only when the facility meets the chapter's added personnel, garbing, monitoring and stability requirements at all times, not only when compounding that specific preparation.

A CSP's category is earned by the room, the process and the testing the preparation went through, not assigned at the point of dispensing. An inspector checks the facility's records against that standard, not the label on the preparation.

Where the Category Framework Does Not Apply

Two carve-outs sit outside the three-category structure. A true immediate-use CSP, compounded for urgent administration to a single patient from no more than three sterile products, with administration starting within four hours of preparation, is exempt from the category system entirely. An outsourcing facility registered under 503B compounds under cGMP, the federal manufacturing standard, rather than under USP 797's category framework, and its reporting obligations after registration run on a separate track from any category a 503A pharmacy would have assigned the same preparation.

USP 797 also carves out a separate set of allergenic extract compounding rules for pharmacies that transfer conventionally manufactured sterile allergen products into sterile vials, with their own personnel, facility and beyond-use date provisions, rather than folding that work into the Category 1, 2 and 3 structure.

Why Early Legal Counsel Is Critical

It is critical that compounding pharmacies promptly retain experienced healthcare defense counsel upon receiving a 483 inspection finding, a warning letter, or any state board inquiry that challenges a facility's USP 797 category or beyond-use dates. Early legal intervention can protect the pharmacy's rights, ensure an accurate and complete response to the finding, avoid inadvertent admissions about the facility's actual compounding environment, preserve relevant defenses, and allow counsel to communicate with the inspecting agency on the pharmacy's behalf. Delaying legal representation can significantly affect the outcome of a matter and expose the pharmacy to license action that proper handling could have avoided.

How Health Law Alliance Can Help

Health Law Alliance represents compounding pharmacies through USP 797 and USP 800 inspection findings, from the initial observation through any state board or FDA response.

Health Law Alliance has represented 2,500+ clients nationwide.

If a compounding pharmacy has received an inspection finding challenging its CSP categories or beyond-use dates, contact Health Law Alliance's compounding pharmacy defense team for a free, confidential consultation before the response window closes.